2011 in Review: Rivaroxaban, Sapien, Mark Midei, Conflicts of Interest, and Much More

Here’s a completely personal review of the past year in cardiology. Please write a comment if you strongly agree, disagree, or think something is missing.

Drug of the Year: Rivaroxaban (Xarelto)– Despite a highly negative review from FDA reviewers, rivaroxaban gained FDA approval for the coveted stroke prevention in AF indication. The drug was approved earlier in the year for VTE prevention after surgery. The biggest surprise, though, was rivaroxaban’s success in ACS in the ATLAS ACS TIMI 51 trial, which may well have an important impact on the field for years to come.

Drug Dog of the Year: Dronedarone (Multaq)It was not a good year for dronedarone. The year started off with warnings about liver toxicity (as first reported here on CardioBrief) and the news didn’t get much better as the year progressed:

Year’s biggest disappointment: Vorapaxer, Merck’s thrombin receptor antagonist–

Dumbing Down the News– As usual, the media did its best to dumb down the news. Here are just a few examples.

Scientific Misconduct and Retractions– I remain shocked that the scientific community continues to ignore the implications of the growing number of cases of scientific misconduct and article retractions.

Mark Midei, Stents, and Device Overuse– Was 2011 the beginning of the end of the device overuse problem or the end of the beginning?

At Long Last:

Editorials and Comments:

RIP:

Article source: http://www.forbes.com/sites/larryhusten/2011/12/31/2011-in-review-rivaroxaban-sapien-mark-midei-conflicts-of-interest-and-much-more/

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *

*